SLC5A2 and Hypoglycemia: Furthermore, the risks of confirmed hypoglycaemia, acute kidney failure and hyperkalaemia were similar between SGLT2 inhibitors and placebo in the EMPA-REG OUTCOME and CANVAS trials12,13.